Drug & intervention

warfarin

RxCUI 11289

Clinical trials49
Recruiting3
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Warfarin

Warfarin, sold under the brand name Coumadin among others, is used as an anticoagulant medication. It is commonly used to prevent deep vein thrombosis and pulmonary embolism, and to protect against stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves. Warfarin may sometimes be prescribed following a ST-segment elevation myocardial infarction and orthopedic surgery. It is usually taken by mouth, but may also be administered intravenously. The common side effect, a natural consequence of reduced clotting, is bleeding. Less common side effects may include areas of tissue damage, and purple toes syndrome. Use is not recommended during pregnancy. The effects of warfarin are typically monitored by checking prothrombin time (INR) every one to four weeks. Many other medications and dietary factors can interact with warfarin, either increasing or decreasing its effectiveness. The effects of warfarin may be reversed with phytomenadione (vitamin K1), fresh frozen plasma, or prothrombin complex concentrate. Warfarin decreases blood clotting by blocking vitamin K epoxide reductase, an enzyme that reactivates vitamin K1. Without sufficient active vitamin K1, the plasma concentrations of clotting factors II, VII, IX, and X are reduced and thus have decreased clotting ability. The anticlotting protein C and protein S are also inhibited, but to a lesser degree. It is wrongly described as a "vitamin K antagonist". This term is incorrect. Warfarin does not antagonize the action of vitamin K1, but rather antagonizes vitamin K1 recycling, depletin...

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinNCT07331389 · 2025-09-24
RECRUITING
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist DeviceNCT06655376 · 2024-10-02
RECRUITING
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on DialysisNCT03862859 · 2019-10-09
RECRUITING
SWITCH: Apixaban vs Vitamin K in HM3NCT07471139 · 2026-08-01
NOT_YET_RECRUITING
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and DigoxinNCT07502001 · 2026-04-08
NOT_YET_RECRUITING
A Study of BGM0504 in Overweight or Obese ParticipantsNCT06920056 · 2025-03-24
COMPLETED
Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy SubjectsNCT06723691 · 2024-12-18
COMPLETED
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504 · 2024-02-27
COMPLETED
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsNCT05815680 · 2023-04-06
COMPLETED
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 · 2022-07-08
COMPLETED
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist DevicesNCT04865978 · 2021-12-14
COMPLETED
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT)NCT04645550 · 2020-11-22
COMPLETED
A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and DiabetesNCT04509193 · 2020-08-21
COMPLETED
PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on ApixabanNCT04142658 · 2020-05-01
TERMINATED
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving DialysisNCT03987711 · 2019-12-10
COMPLETED
Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)NCT03781258 · 2018-11-23
UNKNOWN
Anti-thrombotic Monotherapy With the HeartMate 3 LVASNCT03704220 · 2018-08-16
UNKNOWN
Effect of BIA 5-1058 400 mg on Warfarin PharmacokineticsNCT04994119 · 2018-02-23
COMPLETED
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382NCT03347968 · 2017-11-27
COMPLETED
The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary ThromboembolismNCT03185845 · 2017-06-15
UNKNOWN
MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)NCT03078374 · 2017-01-11
UNKNOWN
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in CancerNCT02744092 · 2016-12-13
COMPLETED
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial FibrillationNCT02942407 · 2016-12-01
COMPLETED
Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet TherapyNCT02836652 · 2016-11-01
COMPLETED
A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced TumorsNCT02422589 · 2015-10-23
COMPLETED
ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)NCT02935855 · 2015-09-01
COMPLETED
Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult SubjectsNCT02461914 · 2015-08-01
COMPLETED
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal DisconnectionNCT02247414 · 2014-09-01
COMPLETED
Use of Ventavis in Patients With Postembolic Residual Pulmonary HypertensionNCT02238535 · 2014-09-01
UNKNOWN
Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic SplenectomyNCT02238444 · 2014-09-01
UNKNOWN
Effect of Opicapone at Steady State on Warfarin PharmacokineticsNCT02305030 · 2014-03-01
COMPLETED
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy SubjectsNCT02070510 · 2014-02-27
COMPLETED
Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy SubjectsNCT02022254 · 2013-12-17
COMPLETED
Drug-drug Interaction Study(Lobeglitazone, Warfarin)NCT02002611 · 2013-12-01
COMPLETED
A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid ArthritisNCT01636557 · 2012-10-11
COMPLETED
A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy ParticipantsNCT01432938 · 2011-09-01
COMPLETED
Drug-drug Interaction Study With MDV3100 and a Cocktail of SubstratesNCT01911728 · 2011-07-25
COMPLETED
Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy SubjectsNCT01311622 · 2011-03-01
COMPLETED
A Study of LY2216684 and Warfarin in Healthy SubjectsNCT01263119 · 2010-12-01
COMPLETED
Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) PatientsNCT01103609 · 2010-04-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.